| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968272 | Vaccine | 2011 | 7 Pages |
Abstract
⺠Anti-HBs seroprotection rate (SPR) [â¥10 mIU/mL] was 100% for mpHBV. ⺠Anti-HBs SPR [â¥10 mIU/mL] was 99% for the licensed control (Comvaxâ¢). ⺠Anti-PRP SPR [â¥0.15 μg/mL] was 97% for mpHBV-Hib. ⺠Anti-PRP [â¥0.15 μg/mL] was 96% for the licensed control (Comvaxâ¢). ⺠The safety profile of mpHBV-Hib was comparable to the licensed control.
Keywords
PolyribosylribitolphosphateVRCGMTAPCPrPHBsAgOmpCHepatitis B surface antigenantigen-presenting cellsSafetyImmunogenicityanalysis of varianceANOVASPRAnti-HBsadverse eventGeometric mean titerSeroprotection rateHaemophilus influenzae type bHepatitis BHBVHibPneumococcal conjugate vaccinehepatitis B virusPCV
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Andrew W. Lee, Timo Vesikari, Christopher L. Gilbert, Stephanie O. Klopfer, Florian P. Schödel, Prakash K. Bhuyan,